CRISPR Therapeutics has crossed a key technical hurdle by surpassing an 80 Relative Strength Rating. The biotech company’s performance signals notable momentum in a competitive market space.

Moran Wealth Management LLC has acquired 13,654 shares of CRISPR Therapeutics AG, reflecting the rising market confidence in the groundbreaking gene-editing field. The investment, worth approximately $664,000, highlights a continued uptick in institutional backing for CRISPR’s innovative biotech research.